ATLANTA, May 1, 2024
/PRNewswire/ -- Optomed USA, Inc.,
a medical technology company, introduces the Optomed Aurora AEYE, a
handheld AI fundus camera that provides instant detection of more
than mild diabetic retinopathy. With the Optomed Aurora AEYE,
diabetic patients in the primary care setting can now get on-the
spot eye screenings and immediate retinopathy detection before
being referred to an eye care professional.
Optomed Aurora with AEYE-DS is the only FDA-cleared handheld AI
fundus camera. Recent clinical trials demonstrated that the Optomed
Aurora AEYE handheld camera exhibits diagnostic sensitivity was in
the range of 92%-93% and specificity was in the range of 89%-94%.
In both studies, over 99% of patients received a diagnostic result.
Its non-mydriatic and single image per eye operation offers quick
and accurate screening. Its high-contrast optical design is
engineered to detect small early-phase retinal changes with a
50-degree field-of-view. The ease-of-use is further increased by
autofocus and auto exposure functions. It has the capability to
capture digital images that can easily be sent to eye care
providers.
Nearly 50% of the 38.4 million Americans who have diabetes skip
their annual eye exams, leaving them vulnerable to diabetic
retinopathy and blindness. Autonomous screening in primary care can
improve clinic adherence to HEDIS measurements, is
reimbursable, and ultimately can prevent blindness in diabetics at
risk for vision loss.
"The Optomed Aurora AEYE gives primary care providers the
opportunity to bridge the diabetic retinopathy gap in the US with
immediate, on-the-spot detection of diabetic retinopathy with
results in about 60 seconds," said David Frasch, Managing
Director. "This technology removes the guesswork out of when it is
necessary to refer a patient to an eye care provider. Results
with the Optomed Aurora AEYE are simple: red means you refer to an
eye care specialist, and green means you screen again in 12
months."
About Optomed
Optomed USA, Inc. a wholly owned subsidiary of Optomed
Plc, a Finnish medical technology company and one of the leading
providers of handheld fundus cameras worldwide. Optomed Plc
combines handheld screening devices with software and optional
artificial intelligence integration with the aim to transform the
diagnostic process of blinding eye-diseases such as rapidly
increasing diabetic retinopathy. In its business, Optomed Plc
focuses on eye-screening devices and software solutions-related
R&D in Finland, and sales
through different channels in over 60 countries.
Forward-Looking Statements
This press release
includes forward-looking statements concerning future events. These
statements involve risks and uncertainties, and actual results may
differ from those expressed or implied. Factors beyond the control
of Optomed Plc and its affiliates may affect future performance.
Optomed Plc and its affiliates rely on third parties for certain
activities, and delays may occur if these parties fail to meet
obligations, regulatory requirements, or deadlines. Optomed Plc and
its affiliates do not commit to updating forward-looking statements
considering future events or changes in expectations.
Contact Information
Optomed USA, Inc.
Theresa Matson
626-437-5950
theresa.matson@optomed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/optomed-releases-first-fda-cleared-handheld-ai-fundus-camera-for-detection-of-more-than-mild-diabetic-retinopathy-302133170.html
SOURCE Optomed USA Inc.